Bionomics files for IPO with SEC - How to buy the stock?

Follow us on Google News:
 Bionomics files for IPO with SEC - How to buy the stock?
Image source: Andrew Angelov,Shutterstock

Highlights

  • Australia-based Bionomics Limited said it has filed for an IPO with the SEC for its stock listing in the US.

  • Bionomics has applied for Nasdaq listing under the ticker "BNOX".

  • Its lead product candidate, BNC210, is used to treat social anxiety disorder and post-traumatic stress disorder.

Australia-based clinical-stage biopharmaceutical company Bionomics Limited on Tuesday filed for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC).

The company is expected to offer American Depositary Shares (ADSs), each of which would represent one or several Bionomics ordinary shares in the US.

Furthermore, the company aims to list the shares on the Nasdaq stock exchange (NASDAQ). Bionomics will offer all its shares in the IPO, the company said in a press release.

However, the company has not yet set any terms regarding the number of shares to be sold or the pricing of the ADSs for the offering.

Also Read: Aadi Bioscience (AADI) stock soars on FDA approval for FYARRO

Bionomics is a biopharmaceutical firm that develops novel drug candidates for treating patients with severe Central Nervous System (CNS) disorders.

Bionomics’ current lead product candidate, BNC210, is used in treating acute social anxiety disorder and chronic post-traumatic stress disorder. The company has a strategic partnership with Merck & Co., Inc. and is undertaking early-stage clinical trials for two Alzheimer's drugs.

Bionomics plans to trade on Nasdaq under the ticker symbol "BNOX".

Its shares are currently listed on the Australian Securities Exchange (ASX) under the ticker symbol "BNO". On completion of the offering in the US market, it will continue to trade on ASX under the "BNO" ticker, the company said in its release.

It is also listed on the US OTCQX Market and trades under the ticker symbol "BNOEF".

The underwriters for the proposed offering are Evercore ISI, Cantor, William Blair, H.C. Wainwright & Co., and Berenberg.

Also Read: Pendo IPO: Software company gearing up for public offer?

Bionomics files for IPO with SEC

Also Read: AeroClean Technologies (AERC) IPO: How to buy the stock?

How to buy the US-listed Bionomics stocks:

A registration statement regarding the IPO has been filed with the SEC. But these securities cannot be sold or accepted before the registration statement becomes effective. In addition, its declaration doesn't offer to sell securities in any jurisdiction, according to the statement.

Also Read: Why did MultiPlan Corporation (MPLN) stock jump 33% today?

Bottomline

Bionomics said that its lead product candidate BNC210 is used in treating acute social anxiety disorder and post-traumatic stress disorder. "There remains a significant unmet medical need for the over 22 million patients in the United States suffering from SAD and PTSD,", the company said. Analysts expect its new drug could be major revenue garner after its clearance.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles